business
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
Key takeaways
- Livestream Menu Make Itselect USAINTLLivestream Search quotes, news & videos Livestream Watchlist SIGN INCreate free account Markets Business Investing Tech Politics Video Watchlist Investing Club PROLivestream Menu
- Eli Lilly on Tuesday announced plans to acquire three companies for almost $4 billion in cash, as it looks to expand its research and development business into infectious diseases.
- The company said it had agreed deals to buy Curevo, Limma Tech Biologics and Vaccine Company for $1.5 billion, $780 million and $1.55 billion, respectively.
Livestream Menu Make Itselect USAINTLLivestream Search quotes, news & videos Livestream Watchlist SIGN INCreate free account Markets Business Investing Tech Politics Video Watchlist Investing Club PROLivestream Menu
Eli Lilly on Tuesday announced plans to acquire three companies for almost $4 billion in cash, as it looks to expand its research and development business into infectious diseases.
The company said it had agreed deals to buy Curevo, Limma Tech Biologics and Vaccine Company for $1.5 billion, $780 million and $1.55 billion, respectively.
Article preview — originally published by CNBC. Full story at the source.
Read full story on CNBC →
More top stories
Also covered by
MarketWatch
This new quantum stock could debut with a valuation of nearly $13 billion
Investing.com
Lilly to acquire three vaccine developers for up to $3.83 billion
Yahoo Finance
Here’s What the Street is Saying About Eli Lilly and Company (LLY)
STAT News
STAT+: Eli Lilly to buy three small vaccine developers
Aggregated and edited by the Scoop newsroom. We surface news from CNBC alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop